Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Wojciech Jurczak, Caroline Dartigeas, Marta Coscia, Peter S. Ganly, Ghassan Al-Jazayrly, Chunxiao Wang, Katherine Bao, Ching Ching Leow, Safi Shahda, Pier Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2021-145938

Published: 2021

Journal Articles

BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Jeff P. Sharman, Wojciech Jurczak, Catherine C. Coombs, Marisa Hill, Denise Wang, Nora C. Ku, Ananya Guntur, Safi Shahda, Ching Ching Leow, Paolo Ghia, Anthony R. Mato

Blood (2021) 138 (Supplement 1): 3736.

https://doi.org/10.1182/blood-2021-145926

Published: 2021

Journal Articles

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Anthony R. Mato, William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu, Safi Shahda, Ching Ching Leow, Constantine S. Tam, Jennifer A. Woyach, Toby A. Eyre

Blood (2021) 138 (Supplement 1): 3742.

https://doi.org/10.1182/blood-2021-145936

Published: 2021